Compare Booking Holdings Inc (BKNG) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Booking Holdings Inc vs Mesoblast Limited — how do they compare? Booking Holdings Inc trades at $213.05 (market cap $159.95B), while Mesoblast Limited trades at $16.74 (market cap $2.21B). The key difference: Booking Holdings Inc is far larger — about 72.4× Mesoblast Limited's market cap, and Booking Holdings Inc pays a 0.79% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| BKNG | MESO | |
|---|---|---|
Market Cap | $159.95B | $2.21B |
Sector | Consumer Cyclical | Technology |
52-Week High | $228.83 | $20.96 |
52-Week Low | $154.13 | $12.88 |
Enterprise Value | $163.43B | $2.21B |
Dividend Yield | 0.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BKNG trades at $212.26, down 0.29% on the day, with a bullish technical signal from moving averages and strong support at $212. The company reported Q2 2026 EPS of $2.54, beating estimates, and revenue growth remains robust, though net income margin dipped to 20.07% in 2025. Analyst consensus is strongly bullish with a $239.31 price target, and recent news highlights resilient travel demand and AI integration efforts.
The outlook for BKNG is positive, driven by earnings beats and solid cash flow, but risks include geopolitical volatility and high debt levels. Upside potential exists if travel demand sustains and margins improve, yet investors face headwinds from competitive pressures and economic sensitivity.
MESO trades at $16.78, up 0.6% with a bullish technical signal from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144% net margin. Recent milestones include Phase 3 trial completion for chronic back pain and BLA filing for heart failure treatment, indicating pipeline progress.
Investment outlook balances promising commercial traction against significant financial losses. The stock offers growth potential from expanding indications but carries high risk due to negative earnings and dependence on regulatory approvals. Analyst consensus leans bullish with 45% buy ratings, though profitability remains the key challenge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Booking Holdings Inc
Booking is the world's largest online travel agency by revenue, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates a number of branded travel booking sites, including Booking.com, Agoda, OpenTable, and Rentalcars.com, and has expanded into travel media with the acquisitions of Kayak and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.
Read more on BKNG →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
